Abstract
The use of interferon alfa-2b (IFN-α2b) as adjuvant therapy for high-risk melanoma has been controversial since it was first found to have
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
